CSCPDTtrial

JRCT ID: jRCTs051180224

Registered date:29/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: central serous chorioretinopathy
• Date of first enrollment: 01/06/2016
• Target sample size: 20
• Study type: Interventional

Intervention(s)

3mg/m2 intravenous infusion of verteporfin over 10 minutes followed by delivery of laser at 15 minutes.
Nonthermal laser light of 689nm wavelength is applied for 83 sec delivering a dose of 50J/cm2 at a light intensity of 0.6W/cm2.

Outcome(s)

• Primary Outcome: Resolution of serous retinal detachment of 1week, 1month, 3months, 6months, and 1year after photodynamic therapy
• Secondary Outcome: visual acuity of 1week, 1month, 3months, 6months, and 1year after photodynamic therapy

Key inclusion & exclusion criteria

• Age minimum: 30age
• Age maximum: 100age
• Gender: Both

Include criteria

1.3 months or more after onset
2.presence of active angiographic leakage under or adjacent to fovea
in fluorescein angiography
3.presence of serous retinal detachment on optical coherence tomography
4.written informed consent

Exclude criteria

1. drug allery to verteporfin
2. pregnant or expecting pregnancy
3. porphyria
4. macular diseases other than central serous chorioretinopathy
5. others (inappropriate case judged by investigator or subinvestigators)

Related Information

• Primary Sponsor: Sotozono Chie
• Secondary ID(s): UMIN000022126